BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare I&I: Opioid-Induced Constipation (OIC) Market Spotlight

November 05, 2018

Opioids are increasingly used to reduce severe chronic and acute noncancerous pain, including spinal osteoarthritis, failed back surgery, and back pain. However, adverse gastrointestinal effects potentially reduce the clinical utility of opioids. Generally, between 40–95% of patients using opioids develop opioid-induced constipation (OIC). It is the most common side-effect, as tolerance does not arise over the long-term, in contrast to what is observed with other symptoms such as vomiting, sedation, and nausea. OIC can occur at any time after the initiation of opioid analgesics, and will negatively affect a patient’s quality of life, psychological wellbeing, work productivity, and daily activity.

This Datamonitor Healthcare report contains a Market Spotlight module.

Disease Group Covered: Gastroenterology (non inflammatory bowel disease)
Back to the top Back to the top